Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00267020 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Study of Gemcitabine or Gemcitabine + Enzastaurin in Participants With Advanced or Metastatic Pancreatic Cancer
A Phase 2 study of Pancreatic Neoplasm, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 130
- Enrollment target
- 1
- Study location
NCT00267020 is a Phase 2 study of Pancreatic Neoplasm that has completed, run by Eli Lilly and Company. The registered enrollment target is 130 participants, below the 647-participant average among 10 other Pancreatic Neoplasm trials with a reported enrollment target (80% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00267020, a Phase 2 study of Pancreatic Neoplasm, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 130 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research study is to determine the effects and toxicity of gemcitabine alone or gemcitabine plus enzastaurin in participants with pancreatic cancer.
Conditions Studied
Interventions
- DRUG gemcitabine
- DRUG enzastaurin
Study Locations (1)
Texas
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559), Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 130 participants |
| Start Date | 2005-12 |
| Est. Completion | 2008-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00267020
The ClinicalTrials.gov registry entry for NCT00267020 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 130 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 647-participant average among 10 other Pancreatic Neoplasm trials with a reported enrollment target (80% lower). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pancreatic Neoplasm appearing as the primary indexed condition, and to 2 interventions - of which gemcitabine is the first listed.
NCT00267020 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT00267020 about?
NCT00267020 is a clinical study titled "Phase 2 Study of Gemcitabine or Gemcitabine + Enzastaurin in Participants With Advanced or Metastatic Pancreatic Cancer". The purpose of this research study is to determine the effects and toxicity of gemcitabine alone or gemcitabine plus enzastaurin in participants with pancreatic cancer.
What is the current status of trial NCT00267020?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 130 participants. The study started on 2005-12. Estimated completion is 2008-05.
What conditions does trial NCT00267020 study?
This clinical trial studies the following conditions: Pancreatic Neoplasm.
What interventions are being tested in trial NCT00267020?
The interventions under investigation include: gemcitabine (DRUG), enzastaurin (DRUG).
Who is sponsoring clinical trial NCT00267020?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00267020 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Neoplasm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Rectus Sheath Block With Liposomal Bupivacaine Versus Thoracic Epidural Analgesia for Pain Control Following Pancreatoduodenectomy
RECRUITING · Phase 2
-
Ultrasound-Guided Verteporfin Photodynamic Therapy for the Treatment of Unresectable Solid Pancreatic Tumors or Advanced Pancreatic Cancer, VERTPAC-02 Study
COMPLETED · Phase 2
-
Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula
RECRUITING · Phase 3
-
Prospective Screening for Pancreatic Ductal Adenocarcinoma in High-Risk Individuals
RECRUITING · Early Phase 1
-
Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors
RECRUITING · Phase 1
-
Evaluation of Endoscopic Ultrasound-Guided Radiofrequency Ablation for the Management of Pancreatic Tumors, ERASE Study
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.